Changelog — 2026-02-19
2026-02-19
AZN
ASTRAZENECA PLC
Status: RECRUITING → SUSPENDED (As a part of portfolio and planning reassessment for the cur)
NCT07247292
• Status: Recruiting → Suspended • Why stopped: As a part of portfolio and planning reassessment for the current period, a decision has been made to prioritize, optimiz…
🚩 MAJOR
2026-02-19
O
ONON
On Holding AG
Enrollment 345→180 (-48%) — NA
NCT05492825
• Na • Enrollment 345→180 (-48%)
MEDIUM
2026-02-19
O
ONON
On Holding AG
Primary endpoint removed: Health-related quality of life — NA
NCT05492825
• Na
MEDIUM
2026-02-19
T
TISI
TEAM INC
Primary endpoint added: Change in Montreal Cognitive Assessment (MoCA) — NA
NCT06936514
• Na
MEDIUM
2026-02-19
L
LXRX
LEXICON PHARMACEUTICALS, INC.
Locations updated — PHASE3
NCT05644561
• Phase 3
MEDIUM
2026-02-19
BSX
BOSTON SCIENTIFIC CORP
Enrollment 20→5 (-75%) — NA
NCT05938283
• Na • Enrollment 20→5 (-75%)
MEDIUM
2026-02-19
AZN
ASTRAZENECA PLC
Enrollment 4→14 (250%) — PHASE3
NCT06512883
• Phase 3 • Enrollment 4→14 (+250%)
MEDIUM
2026-02-19
C
CADL
Candel Therapeutics, Inc.
Enrollment 30→45 (50%) — PHASE2
NCT07332000
• Phase 2 • Enrollment 30→45 (+50%)
MEDIUM
2026-02-19
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Status: NOT_YET_RECRUITING → ACTIVE_NOT_RECRUITING — PHASE3
NCT07144345
• Phase 3 • Status: Not yet recruiting → Active, not recruiting
MEDIUM
2026-02-19
C
CADL
Candel Therapeutics, Inc.
Primary endpoint removed: Biomarkers of immune activation and tumor burden — PHASE2
NCT07332000
• Phase 2
MEDIUM
2026-02-19
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Locations updated — PHASE3
NCT07144345
• Phase 3
MEDIUM
2026-02-19
BSX
BOSTON SCIENTIFIC CORP
Enrollment 500→524 (5%)
NCT06656884
• Enrollment 500→524 (+5%)
MEDIUM
2026-02-19
NVS
NOVARTIS AG
Enrollment 285→288 (1%) — PHASE3
NCT05624749
• Phase 3 • Enrollment 285→288 (+1%)
MEDIUM
2026-02-19
M
MRUS
Merus N.V.
Enrollment 576→194 (-66%) — PHASE1
NCT04868877
• Phase 1 • Enrollment 576→194 (-66%)
MEDIUM
2026-02-19
O
OCGN
Ocugen, Inc.
Status: RECRUITING → ACTIVE_NOT_RECRUITING — PHASE3
NCT06388200
• Phase 3 • Status: Recruiting → Active, not recruiting
MEDIUM
2026-02-19
AZN
ASTRAZENECA PLC
Primary endpoint added: Progression-free Survival Based on Blinded Independent Central Review in All Randomized Participants — PHASE3
NCT05555732
• Phase 3
MEDIUM
2026-02-19
AZN
ASTRAZENECA PLC
Enrollment 192→120 (-38%) — PHASE2
NCT06450197
• Phase 2 • Enrollment 192→120 (-38%)
MEDIUM
2026-02-19
REGN
REGENERON PHARMACEUTICALS, INC.
Locations updated — PHASE3
NCT06246916
• Phase 3
MEDIUM